Comparative Pharmacology
Head-to-head clinical analysis: BRONITIN MIST versus SOMOPHYLLIN DF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONITIN MIST versus SOMOPHYLLIN DF.
BRONITIN MIST vs SOMOPHYLLIN-DF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and blocking adenosine receptors.
For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Primarily renal (approximately 70-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 20-30%.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Category C
Category C
Bronchodilator
Bronchodilator